BioDelivery Sciences International Inc

BioDelivery Sciences International — Investor Presentation (April 2009)

36 slides from BioDelivery Sciences International's investor presentation, Apr 3, 2009

  1. Slide 1: Future Leaders in the Biotech Industry

    All rights reserved Future Leaders in the Biotech Industry April 2, 2009 Dr. Mark A. Sirgo President & Chief Executive Officer NASDAQ: BDSI Exhibit 99.1

  2. Slide 2: Notice Regarding Forward Looking Statements

    Notice Regarding Forward Looking Statements Certain statements contained in this presentation or in other documents of BioDelivery Sciences International, Inc. (the “ Company ” ), along with certain statements that may be made by management of the Company orally in presenting this material, may cont

  3. Slide 3: Corporate Highlights

    Corporate Highlights SPECIALTY PHARMACEUTICAL COMPANY – Leverage novel proprietary patent-protected drug delivery technologies to rapidly advance the commercialization of new applications of proven therapeutics to address unmet market needs HIGH ROI DRUG DEVELOPMENT PLATFORM – Utilize the 505 (b)(2)

  4. Slide 4: Key Value Driver: 1H 2009 Approval of ONSOLIS

    Key Value Driver: 1H 2009 Approval of ONSOLIS™ Anticipated For Breakthrough Cancer Pain August 28, 2008: received a Complete Response Letter ONSOLIS™ Complete Response Content: – Conversion of risk minimization action plan (“RiskMAP”) to a risk evaluation mitigation strategy (“REMS”) – No other defi

  5. Slide 5: Transmucosal Fentanyl Drug Delivery Technologies Competitive Landscape

    Transmucosal Fentanyl Drug Delivery Technologies Competitive Landscape

  6. Slide 6: Transmucosal Fentanyl Delivery Systems

    Transmucosal Fentanyl Delivery Systems Actiq ® (1996) Fentora ® (2006) Formulation : Buccal tablet Administration : Place between cheek and gums above a molar. Allow to dissolve. After 30 minutes, if remnants still remain, swallow with a glass of water. Formulation : Oral transmucosal lozenge Admini

  7. Slide 7: BEMA (BioErodible MucoAdhesive) Film Technology

    BEMA ™ (BioErodible MucoAdhesive) Film Technology Bi-layered film technology Active drug in the muco- adhesive layer Backing layer facilitates unidirectional flow of drug Adheres to oral mucosa in < 5 seconds Dissolves within 15-30 minutes Designed to optimize delivery across the mucosa BEMA attribu

  8. Slide 8: ONSOLIS - Profile and Attributes

    ONSOLIS ™ - Profile and Attributes

  9. Slide 9: Greater and More Rapid Absorption of Fentanyl Compared to Actiq

    ONSOLIS™ 0.0 0.5 1.0 1.5 2.0 Time After Dose Administration (hours) 0.0 0.5 1.0 1.5 2.0 Greater and More Rapid Absorption of Fentanyl Compared to Actiq ® in this PK Study 40% Greater Absorption versus Actiq® The mean peak concentration was higher after ONSOLIS™ than Actiq® The median Tmax was shorte

  10. Slide 10: ONSOLIS: Dose Proportionality Across Dose Range

    1200 µg 600 µg 200 µg ONSOLIS ™: Dose Proportionality Across Dose Range Dose Proportionality Demonstrated Based on Linear Pharmacokinetics 0.0 0.5 1.0 1.5 2.0 2.5 Time (hr) ONSOLIS Plasma Fentanyl Concentrations Vasisht, et al. American Pain Society, Poster Presentation, May 2008.

  11. Slide 11: ONSOLIS Attributes

    Thin Film (simple placement) 2.0% * 0% * 200 – 1200 mcgs 3% * ONSOLIS ™ Attributes Convenient, Easy to use “Adheres – Delivers - Dissolves” Good Oral Tolerability - Incidence of drug-related application site AEs - Discontinued due to application site AEs Provides linear pharmacokinetics across full

  12. Slide 12: ONSOLIS Market Opportunity

    ONSOLIS ™ Market Opportunity

  13. Slide 13: Significant Market Opportunity - Breakthrough Cancer Pain

    1200 1000 1200 Cancer Patients CA + Pain BTP Significant Market Opportunity – Breakthrou g h Cancer Pain Current/Future Market Size: US cancer breakthrough pain market: Branded Drugs - sales estimated to grow from $400 mln ~$1.3 bln by 2017 Current Market Leaders : Fentora ™ : $182 million Actiq ® /

  14. Slide 14: ONSOLIS Commercial Partner

    ONSOLIS ™ Commercial Partner

  15. Slide 15: ONSOLIS Global Commercialization Partner: MEDA AB

    ONSOLIS ™ Global Commercialization Partner*: MEDA AB Intl specialty pharma based in Sweden 2,500 employees/1,650 com ops Sales: 2001 - 2007: $30M $1.3B Significant US presence via MedPointe (Carter Wallace) acquisition in 2007 Therapeutic expertise includes pain/inflammation (Soma ® , tramadol, NSAI

  16. Slide 16: ONSOLIS Represents a Significant Financial Opportunity for BDSI

    ONSOLIS ™ Represents a Significant Financial Opportunity for BDSI Financial Benefits to BDSI $30 million upon NDA approval and commercial launch* $30 million for achievement of specified sales milestones Significant double digit royalty Meda covers all future development costs for ONSOLIS including

  17. Slide 17: Capital Efficient Business Model

    <$25M Total Costs 3 Years Timeline to NDA Product Development Capital Efficient Business Model ONSOLIS ™ – Early and significant return on investment * Approval anticipated 1H09

  18. Slide 18: Medium-Term Product Portfolio

    Medium-Term Product Portfolio

  19. Slide 19: BEMA Buprenorphine: Schedule III Narcotic

    BEMA ™ Buprenorphine: Schedule III Narcotic BDSI’s Entry Into Broader Pain Market Market Need Rapidly escalating problem of opioid abuse and addiction in the US Short and long-term side effect issues with opioids Safety issues with COX-2 inhibitors and NSAIDS Development Goals Initial indication: Po

  20. Slide 20: BEMA Buprenorphine Provides a Potential Alternative to CII Drugs

    BEMA ™ Buprenorphine BEMA ™ Buprenorphine Provides a Potential Alternative to CII Drugs NSAID, COX-2 Weak opioid Severe Pain: Strong opioid Pain persisting or increasing Pain persisting or increasing Acute Pain: • Post operative • Musculoskeletal injuries • Acute low back pain Fentanyl Morphine OxyC

  21. Slide 21: BEMA Buprenorphine Provides a Potential Alternative to CII Drugs

    BEMA ™ Buprenorphine BEMA Buprenorphine Provides a Potential Alternative to CII Drugs Mild Pain: non-opioid Pain persisting or increasing Pain persisting or increasing OxyContin ® Duragesic ® Kadian/Avinza ® Chronic Pain Indications: •Back Pain •Osteoarthritis Tramadol Vicodin ® COX-2’s Naproxen Ibu

  22. Slide 22: Moderate to Severe Pain Market Accounts for Over 50% of Units Sold

    BEMA Buprenorphine will compete for this market segment >50% of units Moderate to Severe Pain Market Accounts for Over 50% of Units Sold Source: Wolters Kluwer Integrated Pharmaceutical Audits. Mild = APAP, salicylate, NSAIDs/COXII, Moderate to severe = hydrocodone, propoxyphene, codeine & combinati

  23. Slide 23: BEMA Buprenorphine: Initial Formulation Pharmacokinetics

    Suboxone 2 mg BEMA™ Buprenorphine Initial Formulation 2 mg BEMA ™ Buprenorphine: Initial Formulation Pharmacokinetics 0.2 0.4 0.6 0.8 1.2 1.4 1.6 Hours

  24. Slide 24: BEMA Buprenorphine PK/PD Study

    Suboxone 2 mg BEMA™ Buprenorphine Initial Formulation 2 mg BEMA™ Buprenorphine NEW Formulation 1 mg BEMA ™ Buprenorphine PK/PD Study – BEMA Buprenorphine Provides Rapid and High Blood Plasma Concentrations Hours 0.2 0.4 0.6 0.8 1.2 1.4 1.6

  25. Slide 25: Bion viivery

    Bion viivery A ANA TY

  26. Slide 26: Slide 26

  27. Slide 27: Slide 27

  28. Slide 28: Slide 28

  29. Slide 29: BEMA Buprenorphine: Market Positioning

    Narcotic of choice in patients requiring acute or chronic pain treatment stepping up from NSAIDs or other non narcotic analgesics BEMA™ Buprenorphine: Market Positioning First Target: moderate to severe acute pain – Post-operative – Musculoskeletal Second Target: moderate to severe chronic pain – Lo

  30. Slide 30: Bioral Drug Delivery Technology

    Bioral ™ Drug Delivery Technology IV Oral Delivery

  31. Slide 31: Bioral Amphotericin B: Potential First Oral Fungicidal

    Bioral™ Amphotericin B: Potential First Oral Fungicidal Market Need Drug resistance to existing oral “fungistatic” agents leads to hospitalization and IV amphotericin B treatment No orally available agents Development Goals First oral fungicidal agent; Potential to prevent hospitalizations and/or fa

  32. Slide 32: Phase 1 Study Results - Bioral Amphotericin B

    Phase 1 Study Results - Bioral ™ Amphotericin B Hours 200 mg 400 mg 800 mg • Bioral ™ Amphotericin B was well-tolerated at single oral doses of & mg • Plasma concentrations of Amphotericin are comparable to prior results from animal studies * Abstract presented at the Focus on Fungal Infections Meet

  33. Slide 33: Bioral Amphotericin B Development Timeline

    Phase 3 Phase 2 Esophageal Candidiasis: Planned for 2011 Leishmaniasis 2010 (DND i , WRAIR)* Single dose pharmacokinetics completed 4Q 2008 Multi-dose pharmacokinetic study 2Q 2009 Phase 1 Bioral™ Amphotericin B Development Timeline* * Research and development partnership with Drugs for Neglected Di

  34. Slide 34: Product Portfolio Summary

    >$200 million * $500 million+* $400 Million* Pre-clinical Phase I Phase II Phase III NDA Filed Marketed Product ONSOLIS™ ( fentanyl buccal soluble film) Breakthrough Cancer Pain** BEMA™ Buprenorphine Moderate to Severe Pain Bioral ™ Amphotericin B Fungal Infections * peak sales potential, BDSI estim

  35. Slide 35: 2009 Financial Highlights

    2009 Financial Highlights ONSOLIS ™ NDA Approval & Launch Royalty on Sales of ONSOLIS ™ Cash Flow Positive From Operations $30.0 Million* Double-digit > $30 Million Potential Includes $3.0 million advance received January 2009

  36. Slide 36: Investor Highlights: BDSI

    Investor Highlights: BDSI* Near-Term Product Opportunity: ONSOLIS ™ (BEMA ™ Fentanyl) approval anticipated in 1H 2009, Strong Commercial Partner making ONSOLIS ™ #1 Global Priority Medium-Term Product Potential (BEMA ™ Buprenorphine, Bioral ™ Amphotericin B) = Revenue Growth Potential 2009 Key Finan

Biodelivery Sciences International — Investor Presentation (April 2009) on 6ix